Precision medicine aims to match the right therapy to the right patient at the right time, improving efficacy and reducing side effects. In this webinar, Dr. Hsu discusses his work to develop personalized treatments for gastrointestinal (GI) cancer patients by creating patient-derived tumor models of cancer (PDMC) that predict how well a patient will respond to therapy. The approach includes a new miniature MicroOrganoSphere™ (MOS™) 3-D tissue model. In his work, Dr. Hsu utilizes the SH800 Cell Sorter to analyze and validate MOS and 10x Genomics’ Single Cell 3' chemistry to perform molecular profiling of these clinical samples. Dr. Hsu’s promising technology is currently undergoing a clinical trial for colorectal cancer at Duke University.

Key Learning Objectives:

  • Understand the innovative features of MOS and assess their ability to accurately represent a patient's unique tumor landscape, while contrasting them with traditional cancer treatments.
  • Discover the contribution of 10x Genomics technology in supporting and enhancing the development of this precision oncology platform.
  • Explore the capabilities of the SH800 Cell Sorter in the development of precision therapies utilizing PDMC.

 

Who should attend

Oncologists, researchers, pharmaceutical professionals, clinicians, regulatory experts, and patient advocates interested in precision medicine and cancer care.

 

Speakers

Portrait of David HsuDavid Hsu, MD, PhD
Associate Professor of Medicine
Duke University School of Medicine
Duke Cancer Institute

David Hsu is an Associate Professor at Duke University's Division of Medical Oncology and Duke Cancer Institute and specializes in GI cancer treatment. He earned his MD, PhD from the University of North Carolina, Chapel Hill, and completed his residency and fellowship at UT Southwestern and Duke University, respectively. His research focuses on patient-derived cancer models like organoids and xenografts, coupled with genomic strategies to enhance GI cancer prognosis and treatment. Recently, he developed MOS™, a microfluidic-based precision oncology approach enabling rapid tumor development (10–14 days) for prognostic and predictive biomarkers.

Portrait of Ryan Mote, PhDRyan Mote, PhD
Science and Technology Advisor
10x Genomics

Dr. Ryan Mote graduated with his PhD from the University of Georgia, focusing his research efforts on integrating multi-modal, high-dimensional genomics and metabolomics datasets to take a more holistic approach towards understanding complex diseases. In his current role as Science and Technology Advisor, Ryan focuses on enabling researchers in adopting cutting edge single cell and spatial technologies.